(Q35581005)

9 August 2017

1 reference

title

Endothelin inhibition: novel therapy for prostate cancer (English)

1 reference

9 August 2017

Endothelin Inhibition: Novel Therapy for Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

31 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

31 March 2024

author name string

Joel B. Nelson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14610413

31 March 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

http://api.elsevier.com/content/article/PII:S0022534701682594?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

http://api.elsevier.com/content/article/PII:S0022534701682594?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

http://www.jurology.com/doi/pdf/10.1097/01.ju.0000096372.07687.86

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

31 March 2024

1 reference

9 August 2017

volume

170

1 reference

9 August 2017

issue

6 Pt 2

1 reference

9 August 2017

page(s)

S65-7; discussion S67-8

1 reference

Interleukin-6: a candidate mediator of human prostate cancer morbidity

9 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

31 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

31 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer

31 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

31 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

Binding and functional properties of endothelin receptor subtypes in the human prostate

31 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

Expression of endothelin receptor a associated with prostate cancer progression

31 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

CpG-rich islands and the function of DNA methylation

31 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

31 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

31 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096372.07687.86

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference